泰林生物(300813) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥78,946,553.19, representing a 10.36% increase compared to ¥71,534,758.17 in the same period last year[5] - Net profit attributable to shareholders was ¥17,575,025.59, up 26.21% from ¥13,925,179.08 year-on-year[5] - Total operating revenue for Q1 2023 was CNY 78,946,553.19, an increase of 10.8% compared to CNY 71,534,758.17 in Q1 2022[19] - Net profit for Q1 2023 reached CNY 17,575,025.59, representing a 26.5% increase from CNY 13,925,179.08 in Q1 2022[20] - Basic earnings per share decreased by 22.22% to ¥0.21 from ¥0.27 in the same period last year[5] - Basic earnings per share for Q1 2023 were CNY 0.21, down from CNY 0.27 in Q1 2022[21] - Other income for Q1 2023 was CNY 4,217,745.67, significantly higher than CNY 105,289.96 in Q1 2022[19] Cash Flow - The net cash flow from operating activities was -¥17,807,115.09, a significant decline of 611.56% compared to -¥2,502,547.74 in the previous year[5] - The net cash flow from operating activities for Q1 2023 was -CNY 17,807,115.09, compared to -CNY 2,502,547.74 in Q1 2022, indicating a decline in cash flow[22] - The net cash flow from investing activities was -61,746,781.25 CNY, compared to -55,585,743.44 CNY in the previous period, indicating an increase in cash outflow[23] - Cash inflow from financing activities totaled 3,000,000.00 CNY, significantly lower than 205,800,000.00 CNY in the previous period[23] - The net cash flow from financing activities was -9,908.47 CNY, a sharp decline from 204,469,339.64 CNY in the previous period[23] - The total cash and cash equivalents at the end of the period were 202,059,043.61 CNY, down from 319,191,845.37 CNY in the previous period[23] - The net increase in cash and cash equivalents was -79,563,804.81 CNY, contrasting with an increase of 146,371,343.00 CNY in the previous period[23] - The company reported a total cash outflow from investing activities of 81,768,109.55 CNY, compared to 75,645,743.44 CNY in the previous period[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥922,917,372.63, a slight increase of 0.03% from ¥922,660,005.83 at the end of the previous year[5] - The total assets of Zhejiang Tailin Biotechnology Co., Ltd. as of March 31, 2023, amounted to CNY 922,917,372.63, showing a slight increase from CNY 922,660,005.83 at the beginning of the year[16] - The company's cash and cash equivalents decreased to CNY 548,796,995.73 from CNY 577,153,986.25, reflecting a decline of approximately 4.5%[16] - Accounts receivable increased to CNY 54,583,843.48 from CNY 42,578,297.85, representing a growth of about 28.3%[16] - Inventory decreased to CNY 107,337,687.08 from CNY 111,201,218.36, indicating a reduction of approximately 3.4%[16] - Current liabilities decreased to CNY 105,402,583.19 from CNY 129,326,260.25, a decline of about 18.5%[17] - The total liabilities decreased to CNY 254,205,720.40 from CNY 275,205,185.78, reflecting a decrease of approximately 7.6%[17] - The company's total equity attributable to shareholders increased to CNY 668,711,652.23 from CNY 647,454,820.05 year-over-year[18] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 12,781[10] - The largest shareholder, Ye Daling, holds 53.48% of the shares, totaling 44,480,000 shares[10] - The company has a significant shareholder, Ye Daling, holding 11,120,000 shares, which is 5.83% of the total shares[11] - The company reported a total of 56,644,160 shares under lock-up agreements, with 18,379,640 shares released during the period[14] Research and Development - The company plans to maintain its focus on research and development of new products and technologies to enhance market competitiveness[12] - Research and development expenses for Q1 2023 were CNY 13,945,439.84, slightly up from CNY 13,701,030.39 in the previous year[19] Other Information - The company received government subsidies amounting to ¥1,835,702.90 during the reporting period[6] - The company did not conduct an audit for the first quarter report[24] - The company is exploring opportunities for market expansion and potential mergers and acquisitions to drive growth[12] - The company reported a decrease in financial asset impairment losses to -CNY 176,430.03 from -CNY 323,417.79 in the previous year[20]